These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31129911)

  • 1. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial.
    Ubaid S; Ford TJ; Berry C; Murray HM; Wrigley B; Khan N; Thomas MR; Armesilla AL; Townend JN; Khogali SS; Munir S; Martins J; Hothi SS; McAlindon EJ; Cotton JM
    Thromb Haemost; 2019 Jul; 119(7):1171-1181. PubMed ID: 31129911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial).
    Bulluck H; Chong JH; Bryant J; Annathurai A; Chai P; Chan M; Chawla A; Chin CY; Chung YC; Gao F; Ho HH; Ho AFW; Hoe J; Imran SS; Lee CH; Lim B; Lim ST; Lim SH; Liew BW; Zhan Yun PL; Ong MEH; Paradies V; Pung XM; Tay JCK; Teo L; Ting BP; Wong A; Wong E; Watson T; Chan MY; Keong YK; Tan JWC; Hausenloy DJ;
    Circulation; 2024 Jul; 150(2):91-101. PubMed ID: 38742915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
    Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
    Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translation of experimental cardioprotective capability of P2Y
    Hjortbak MV; Olesen KKW; Seefeldt JM; Lassen TR; Jensen RV; Perkins A; Dodd M; Clayton T; Yellon D; Hausenloy DJ; Bøtker HE;
    Basic Res Cardiol; 2021 May; 116(1):36. PubMed ID: 34037861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
    Franchi F; Rollini F; Cho JR; Bhatti M; DeGroat C; Ferrante E; Dunn EC; Nanavati A; Carraway E; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2015 Sep; 8(11):1457-1467. PubMed ID: 26404199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet inhibition to target reperfusion injury trial: Rationale and study design.
    Bulluck H; Chan MHH; Bryant JA; Chai P; Chawla A; Chua TS; Chung YC; Fei G; Ho HH; Ho AFW; Hoe AJ; Imran SS; Lee CH; Lim SH; Liew BW; Yun PLZ; Hock MOE; Paradies V; Roe MT; Teo L; Wong AS; Wong E; Wong PE; Watson T; Chan MY; Tan JW; Hausenloy DJ
    Clin Cardiol; 2019 Jan; 42(1):5-12. PubMed ID: 30421441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
    Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.
    van Leeuwen MAH; van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Ten Cate TJF; Piek JJ; von Birgelen C; Escaned J; Valgimigli M; Diletti R; Riksen NP; van Mieghem NM; Nijveldt R; van Royen N
    Circulation; 2019 Jan; 139(5):636-646. PubMed ID: 30586720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-dependent benefits of pre-treatment with new oral P2Y
    Pepe M; Cafaro A; Paradies V; Signore N; Addabbo F; Bortone AS; Navarese EP; Contegiacomo G; Forleo C; Bartolomucci F; Di Cillo O; Bianchi FP; Zanna D; Favale S
    Catheter Cardiovasc Interv; 2019 Mar; 93(4):592-601. PubMed ID: 30269413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
    Greenbaum AB; Ohman EM; Gibson CM; Borzak S; Stebbins AL; Lu M; Le May MR; Stankowski JE; Emanuelsson H; Weaver WD
    Am Heart J; 2007 Oct; 154(4):702-9. PubMed ID: 17892995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial.
    Crimi G; Pica S; Raineri C; Bramucci E; De Ferrari GM; Klersy C; Ferlini M; Marinoni B; Repetto A; Romeo M; Rosti V; Massa M; Raisaro A; Leonardi S; Rubartelli P; Oltrona Visconti L; Ferrario M
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1055-63. PubMed ID: 24156966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cangrelor Use Patterns and Transition to Oral P2Y
    Rymer JA; Bhatt DL; Angiolillo DJ; Diaz M; Garratt KN; Waksman R; Edwards L; Tasissa G; Salahuddin K; El-Sabae H; Dell'Anna C; Davidson-Ray L; Washam JB; Ohman EM; Wang TY
    J Am Heart Assoc; 2022 Jun; 11(11):e024513. PubMed ID: 35621210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
    Gargiulo G; Esposito G; Avvedimento M; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Tebaldi M; Cirillo P; Hunziker L; Vranckx P; Leonardi S; Heg D; Windecker S; Valgimigli M
    Circulation; 2020 Aug; 142(5):441-454. PubMed ID: 32795098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction.
    Abo-Aly M; George B; Shokri E; Chelvarajan L; El-Helw M; Smyth SS; Abdel-Latif A; Ziada K
    J Thromb Thrombolysis; 2021 Oct; 52(3):934-940. PubMed ID: 33258102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.